HIV Infections Clinical Trial
Official title:
Text Messaging to Improve Adherence to Post-Operative Clinic Appointments and Reduce Early Resumption of Sexual Intercourse After Adult Male Circumcision: A Randomized Controlled Trial
Male circumcision (MC) reduces, by more than half, the risk of HIV-1 acquisition. WHO and
UNAIDS recommend that "male circumcision should be recognized as an efficacious intervention
for HIV prevention especially in countries and regions with heterosexual HIV epidemics and
low male circumcision prevalence." As a result, programs have been introduced and scaled up
for voluntary medical male circumcision. Kenya leads with the largest expansion of services.
Early resumption of sexual intercourse after MC may have deleterious effects, including
higher rates of post-operative surgical complications, and higher HIV acquisition among
females in couples that resume sexual activity before certified wound healing. In the
context of rapid scale-up of MC, adherence to post-operative clinic appointments allows
clinicians to assess wound healing and to deliver risk reduction counseling. Abstinence from
sexual intercourse before complete wound healing would reduce the rate of post-operative
adverse events and minimize the risk of HIV transmission from HIV-infected men to their
uninfected female partners.
To the investigators knowledge, the effect of reminders delivered via text messaging to
promote adherence to clinic visits and abstinence after MC has not been investigated. The
investigators propose a randomized controlled trial in which men who will have undergone
voluntary medical male circumcision at selected sites in Kisumu will be randomized to
receive either the intervention (context-sensitive text messages after circumcision) or the
control condition (usual care). This study seeks to determine (a) the effect of regular text
messages sent to men after circumcision on attendance of the scheduled 7-day post-operative
clinic visit versus usual care; (b) the proportion of men who resume sexual activity before
42 days post-procedure after receiving regular text messages versus usual care within the 42
days post-circumcision; and (c) to identify potential predictors of failure to attend the
scheduled 7-day post-operative visit and early resumption of sexual intercourse.
Status | Completed |
Enrollment | 1200 |
Est. completion date | June 2011 |
Est. primary completion date | March 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male - 18 years or older - Have undergone circumcision on the day they are screened for the study - Currently own a mobile phone with text-messaging capability, and - Have the mobile phone in their possession at the time of enrollment - Able and willing to respond to a questionnaire administered via a phone call Exclusion Criteria: - Prior participation in a study on male circumcision - Currently participating in other ongoing research studies - Any medical condition or situation exists such that study participation would not be in the man's best interest, as determined by the investigator |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Kenya | Nyanza Reproductive Health Society | Kisumu | Nyanza |
Lead Sponsor | Collaborator |
---|---|
University of Washington | Kenya Medical Research Institute, University of Illinois at Chicago |
Kenya,
Odeny TA, Bailey RC, Bukusi EA, Simoni JM, Tapia KA, Yuhas K, Holmes KK, McClelland RS. Effect of text messaging to deter early resumption of sexual activity after male circumcision for HIV prevention: a randomized controlled trial. J Acquir Immune Defic — View Citation
Odeny TA, Bailey RC, Bukusi EA, Simoni JM, Tapia KA, Yuhas K, Holmes KK, McClelland RS. Text messaging to improve attendance at post-operative clinic visits after adult male circumcision for HIV prevention: a randomized controlled trial. PLoS One. 2012;7( — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of men failing to return for a post-operative clinic visit at 7 days. | This proportion will be determined by examining each participant's clinic records after their 7th post-operative day. Adherence to this clinic visit will be analyzed as a dichotomous variable. | 7 days | No |
Primary | Proportion of men who report resumption of sexual activity before 42 days post-circumcision. | This proportion will be determined by self-report using a brief questionnaire delivered via phone call. The analysis will be as a dichotomous variable, with participants considered as having either 'resumed' or 'not resumed.' | 42 days | No |
Secondary | Time to resumption of sex by study arm | 42 days | No | |
Secondary | Correlates of failure to attend the scheduled 7-day post-operative visit | 42 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |